PTPN1 and type 2 diabetes mellitus: Moreover, a growing body of evidence suggests that decreasing PTP1B in various tissues, including the muscle, liver and brain, may lead to a multitude of beneficial effects, which indicates that PTPases inhibitors provide a promising tool for the management of different metabolic conditions, such as type 2 diabetes and cancer [12,36,37].